DK1149910T3 - Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion - Google Patents

Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion

Info

Publication number
DK1149910T3
DK1149910T3 DK01109013T DK01109013T DK1149910T3 DK 1149910 T3 DK1149910 T3 DK 1149910T3 DK 01109013 T DK01109013 T DK 01109013T DK 01109013 T DK01109013 T DK 01109013T DK 1149910 T3 DK1149910 T3 DK 1149910T3
Authority
DK
Denmark
Prior art keywords
infection
pharmaceutical preparation
polypeptide
treating
treating papillomavirus
Prior art date
Application number
DK01109013T
Other languages
Danish (da)
English (en)
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1149910(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1149910T3 publication Critical patent/DK1149910T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01109013T 1996-07-30 1997-07-29 Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion DK1149910T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (1)

Publication Number Publication Date
DK1149910T3 true DK1149910T3 (da) 2004-08-02

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01109013T DK1149910T3 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
DK97935646T DK0862634T4 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat mod papillomavirustumorer og -infektioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97935646T DK0862634T4 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat mod papillomavirustumorer og -infektioner

Country Status (12)

Country Link
EP (2) EP0862634B2 (enExample)
JP (2) JP4070815B2 (enExample)
AT (2) ATE265535T1 (enExample)
AU (1) AU736720B2 (enExample)
CA (1) CA2234263C (enExample)
DE (2) DE69728914T2 (enExample)
DK (2) DK1149910T3 (enExample)
ES (2) ES2215805T3 (enExample)
FR (1) FR2751879B1 (enExample)
HK (1) HK1043809B (enExample)
PT (2) PT1149910E (enExample)
WO (1) WO1998004705A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble in ICAM-1 as a biomarker for predicting therapeutic response
DK2411815T3 (en) 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
MX2012000979A (es) 2009-07-21 2012-06-08 Transgene Sa Composición enzimática para la digestión de embriones de pollo.
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX378901B (es) 2014-12-01 2025-03-10 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
IE910909A1 (en) 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK1298211T3 (da) * 1991-07-19 2006-11-13 Univ Queensland Polynukleotidsegment af HPV16-genom
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
EP0789774A2 (en) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
DE69706825T2 (de) 2002-05-02
DE69706825D1 (de) 2001-10-25
EP0862634B2 (fr) 2006-03-01
PT862634E (pt) 2002-03-28
ES2215805T3 (es) 2004-10-16
DE69706825T3 (de) 2006-08-24
ATE205881T1 (de) 2001-10-15
HK1043809B (zh) 2004-12-03
AU736720B2 (en) 2001-08-02
ES2163795T3 (es) 2002-02-01
DE69728914T2 (de) 2005-04-07
AU3855297A (en) 1998-02-20
DK0862634T3 (da) 2002-01-21
CA2234263A1 (fr) 1998-02-05
FR2751879A1 (fr) 1998-02-06
PT1149910E (pt) 2004-09-30
DE69728914D1 (de) 2004-06-03
CA2234263C (fr) 2009-10-13
EP1149910B1 (fr) 2004-04-28
DK0862634T4 (da) 2006-05-08
FR2751879B1 (fr) 1998-10-30
WO1998004705A1 (fr) 1998-02-05
ATE265535T1 (de) 2004-05-15
JP2000500662A (ja) 2000-01-25
JP4198735B2 (ja) 2008-12-17
JP2007254474A (ja) 2007-10-04
JP4070815B2 (ja) 2008-04-02
HK1043809A1 (en) 2002-09-27
ES2163795T5 (es) 2006-07-16
EP0862634B1 (fr) 2001-09-19
EP0862634A1 (fr) 1998-09-09
EP1149910A1 (fr) 2001-10-31

Similar Documents

Publication Publication Date Title
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
EA200000584A2 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
NO924172D0 (no) Substituerte bifenylpyridoner
EA199901031A1 (ru) Производные бензимидазола
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
FI891361A0 (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
AU589939B2 (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
FI923347A0 (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
DK0714387T3 (da) Hidtil ukendte bis-naphthalimider til behandling af cancer
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
AU1192397A (en) Substituted thiazolines and their use for controlling animal pests
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
MY101169A (en) Novel phenylureas
AU6722498A (en) Disubstituted biphenyloxazolines
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
ES2178830T3 (es) Procedimiento para la preparacion de tetraazamacrociclos.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi